Ceredase-J0205 and cerezyme (imiglucerase)-J1785 are drugs indicated for use as an enzyme replacement therapy for patients with a confirmed diagnosis and exhibiting signs and symptoms of Type I (adult) Gauchers disease (lipid metabolism disorder).
Coverage for therapeutic injections is determined according to individual or group customer benefits.
Ceredase and cerezyme are indicated for treatment when one or more of the following conditions exists in patients with Type I Gauchers disease:
- Anemia with hemoglobin of:
10 grams or less for females
12 grams or less for males
- Thrombocytopenia of 50,000 platelets or less and/or documented episodes of thrombocytopenic bleeding
- Multiple bony lesions involving marrow and/or cortex (must be more than 3 bone lesions in number) and/or pathologic fracture of bone
- Significant hepatomegaly or splenomegaly in association with thrombocytopenia
|